Targeting MAPK4 emerges as a promising therapy for prostate cancer

The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease. Research led by Baylor College of Medicine reveals in the Journal of Clinical Investigation that the enzyme MAPK4 concertedly activates androgen receptor (AR) and AKT, molecules at the core of two cellular signaling pathways known to promote prostate cancer growth and resistance […]

Read more

Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard

The results of a Phase III randomized clinical trial have shown that when it comes to detecting clinically significant prostate cancer, Magnetic Resonance Imaging (MRI) with targeted biopsies (MRI-TBx) matches the current standard and brings a multitude of advantages. The PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures (PRECISE) study will help to make prostate cancer diagnosis […]

Read more

Lucrin

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. LUCRIN® INJECTION Leuprorelin acetate Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Lucrin Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks […]

Read more

GenRx Cyproterone 100mg

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. GENRX CYPROTERONE 100 MG TABLETS Contains the active ingredient cyproterone (as cyproterone acetate) Consumer Medicine Information   What is in this leaflet Read this leaflet carefully before taking your medicine. This leaflet answers some common questions about cyproterone. It does not contain all the available information. It […]

Read more

Some Outcomes Worse for Black Men With Low-Risk Prostate Cancer

WEDNESDAY, Nov. 4, 2020 — African-American men with low-risk prostate cancer have a significantly increased 10-year cumulative incidence of disease progression and definitive treatment than non-Hispanic White men, according to a study published in the Nov. 3 issue of the Journal of the American Medical Association. Rishi Deka, Ph.D., from the VHA San Diego Health Care System in La Jolla, […]

Read more

Private and public prostate cancer patients are being treated differently

Men seeking prostate cancer treatment within the private health system were more likely to opt for more radical treatment than men in the public system, according to research published online today by the Medical Journal of Australia. Dr. Luc te Marvelde, a Research Fellow at Cancer Council Victoria, and colleagues analyzed Victorian Cancer Registry data linked to population-based administrative health […]

Read more

Q&A: Advances in ablation for prostate cancer

DEAR MAYO CLINIC: My husband was diagnosed with prostate cancer, and we are looking at treatment options. One doctor suggested a prostatectomy, but my husband finds ablation appealing because of quality of life advantages. I’ve been reading about ablations and came across information about different techniques. I am wondering if one technique or process is better, or if surgery is […]

Read more

Breast cancer drug set to transform prostate cancer treatment

A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice. Final results from the trial showed that olaparib—a pioneering type of drug called a PARP inhibitor and the first ever […]

Read more
1 2 3